IRIS Accounts Production v24.3.2.46 12242968 Board of Directors 1.6.23 31.5.24 31.5.24 0 0 false true false false false true false Ordinary £1 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh122429682023-05-31122429682024-05-31122429682023-06-012024-05-31122429682022-05-31122429682022-06-012023-05-31122429682023-05-3112242968ns15:EnglandWales2023-06-012024-05-3112242968ns14:PoundSterling2023-06-012024-05-3112242968ns10:Director12023-06-012024-05-3112242968ns10:PrivateLimitedCompanyLtd2023-06-012024-05-3112242968ns10:SmallEntities2023-06-012024-05-3112242968ns10:AuditExempt-NoAccountantsReport2023-06-012024-05-3112242968ns10:SmallCompaniesRegimeForDirectorsReport2023-06-012024-05-3112242968ns10:SmallCompaniesRegimeForAccounts2023-06-012024-05-3112242968ns10:FullAccounts2023-06-012024-05-311224296812023-06-012024-05-3112242968ns10:OrdinaryShareClass12023-06-012024-05-3112242968ns10:Director22023-06-012024-05-3112242968ns10:RegisteredOffice2023-06-012024-05-3112242968ns5:CurrentFinancialInstruments2024-05-3112242968ns5:CurrentFinancialInstruments2023-05-3112242968ns5:ShareCapital2024-05-3112242968ns5:ShareCapital2023-05-3112242968ns5:RetainedEarningsAccumulatedLosses2024-05-3112242968ns5:RetainedEarningsAccumulatedLosses2023-05-3112242968ns5:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3112242968ns5:PatentsTrademarksLicencesConcessionsSimilar2023-06-012024-05-3112242968ns5:IntangibleAssetsOtherThanGoodwill2023-05-3112242968ns5:IntangibleAssetsOtherThanGoodwill2024-05-3112242968ns5:IntangibleAssetsOtherThanGoodwill2023-05-3112242968ns5:WithinOneYearns5:CurrentFinancialInstruments2024-05-3112242968ns5:WithinOneYearns5:CurrentFinancialInstruments2023-05-3112242968ns10:OrdinaryShareClass12024-05-31122429681ns10:Director12023-05-31122429681ns10:Director12022-05-31122429681ns10:Director12023-06-012024-05-31122429681ns10:Director12022-06-012023-05-31122429681ns10:Director12024-05-31122429681ns10:Director12023-05-3112242968ns10:Director222023-05-3112242968ns10:Director222022-05-3112242968ns10:Director222023-06-012024-05-3112242968ns10:Director222022-06-012023-05-3112242968ns10:Director222024-05-3112242968ns10:Director222023-05-31
REGISTERED NUMBER: 12242968 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 May 2024

for

Devine Pharmacy Ltd

Devine Pharmacy Ltd (Registered number: 12242968)






Contents of the Financial Statements
for the Year Ended 31 May 2024




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 3 to 5


Devine Pharmacy Ltd

Company Information
for the Year Ended 31 May 2024







DIRECTORS: O Ilevbare
Mrs O J Ilevbare





REGISTERED OFFICE: Suite 1
Concept House
23 Billet Lane
Hornchurch
Essex
RM11 1XP





REGISTERED NUMBER: 12242968 (England and Wales)





ACCOUNTANTS: Havard & Associates
Suite 1
Concept House
23 Billet Lane
Hornchurch
Essex
RM11 1XP

Devine Pharmacy Ltd (Registered number: 12242968)

Statement of Financial Position
31 May 2024

31.5.24 31.5.23
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 330,000 330,000

CURRENT ASSETS
Debtors 5 19,239 79,986
Cash at bank 39 3,211
19,278 83,197
CREDITORS
Amounts falling due within one year 6 212,810 311,890
NET CURRENT LIABILITIES (193,532 ) (228,693 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

136,468

101,307

CAPITAL AND RESERVES
Called up share capital 7 100 100
Retained earnings 136,368 101,207
SHAREHOLDERS' FUNDS 136,468 101,307

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 May 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 May 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 21 February 2025 and were signed on its behalf by:





O Ilevbare - Director


Devine Pharmacy Ltd (Registered number: 12242968)

Notes to the Financial Statements
for the Year Ended 31 May 2024

1. STATUTORY INFORMATION

Devine Pharmacy Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Shares purchased are being amortised evenly over their estimated useful life of nil years.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

Devine Pharmacy Ltd (Registered number: 12242968)

Notes to the Financial Statements - continued
for the Year Ended 31 May 2024

4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 June 2023
and 31 May 2024 330,000
NET BOOK VALUE
At 31 May 2024 330,000
At 31 May 2023 330,000

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.5.24 31.5.23
£    £   
Other debtors 19,239 79,986

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.5.24 31.5.23
£    £   
Bank loans and overdrafts 207,807 269,587
Trade creditors (1 ) -
Taxation and social security 4,050 3,772
Other creditors 954 38,531
212,810 311,890

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.5.24 31.5.23
value: £    £   
100 Ordinary £1 £1.00 100 100

8. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 31 May 2024 and 31 May 2023:

31.5.24 31.5.23
£    £   
O Ilevbare
Balance outstanding at start of year 8,172 -
Amounts advanced 22,698 8,172
Amounts repaid (2,172 ) -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 28,698 8,172

Devine Pharmacy Ltd (Registered number: 12242968)

Notes to the Financial Statements - continued
for the Year Ended 31 May 2024

8. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES - continued

Mrs O J Ilevbare
Balance outstanding at start of year 8,172 -
Amounts advanced 22,698 8,172
Amounts repaid (2,172 ) -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 28,698 8,172

Interest has been charged on the directors loans at a rate of 2.5% per annum in accordance with an approved methodology provided by the U.K. tax authority where appropriate.